PRA

ProAssuranceD

NYSE / Insurance

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

35%

Probability

Target price

$25.00

+2.4% vs current

Most likely

Base case

45%

Probability

Target price

$24.80

+1.6% vs current

B-

Bear case

20%

Probability

Target price

$22.00

-9.9% vs current

AI sentiment snapshot

Latest data as of 2026-05-14

AI commentary

This was a T+3 earnings follow-up, but the queue metadata referenced May 11, 2026 while the company actually reported results on May 5, 2026 through its 8-K and press release. News tone was mildly positive because profitability, operating income, reserve development, and pricing improved, but post-print analyst revision evidence was thin. By May 13, 2026 the stock was still at $24.60, close to the $25.00 cash deal value, which suggests the market remains focused on merger-close probability rather than on a standalone earnings rerating. The evidence supports continued monitoring, not a stronger conviction call.

RankAlpha Sentiment Codex - 2026-05-14

Open post-earnings memo

Evidence flagged

memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-05-31catalystQ1 results showed better underwriting and reserve development but limited standalone rerating roomMedium impact

For the quarter ended March 31, 2026, net income improved to $8.5 million and non-GAAP operating income to $12.7 million, while consolidated calendar-year net loss ratio improved to 77.9% from 80.4% and favorable prior-year reserve development rose to $4.9 million. That supports better earnings quality, but upside is capped while the merger consideration anchors valuation. [#8-K-2026-05-05] [#10-Q-2026-05-05]

2026-06-30eventPending $25.00-per-share cash merger remains the main driverMedium impact

ProAssurance disclosed that The Doctors Company merger would pay $25.00 per share in cash, with final insurance-regulatory approvals received in Alabama, the District of Columbia, Illinois, Missouri, Texas, and Vermont as of May 5, 2026, while California and Pennsylvania reviews remained pending; management still said it anticipated closing by June 30, 2026. With the May 13, 2026 anchor price at $24.60, the stock is trading as a merger-spread monitoring situation rather than a pure operating rerating. [#10-Q-2026-05-05]

2026-12-31catalystMedical professional liability pricing and new-business momentum support downside monitoring if closing slipsMedium impact

Specialty P&C new business rose to $13.6 million from $6.4 million, retention was 83%, and renewal pricing increased 6% in the first quarter, while management said expected loss ratios benefited from underwriting actions and pricing discipline. If the merger timetable slips, these operating trends matter for downside support, though they are secondary to deal completion risk and do not create a high-conviction standalone upside thesis. [#10-Q-2026-05-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-14 • Updated nightlySource: Internal modelMethodology